There is much to love about dividend stocks beyond their passive-income potential. Companies that distribute regular and consistent dividends tend to have rock-solid businesses that can survive in the most challenging environment. Also, opting for dividend reinvestment can substantially boost returns over the long run.
Bristol Myers Squibb (BMY) closed at $72.45 in the latest trading session, marking a -0.74% move from the prior day.
Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.